RE: Patience is key16 Jun 2020 14:35
Exert taken from Faron website, not sure if been mentioned
About HIBISCUS
Human Interferon Beta In Severe CoronavirUS (HIBISCUS) study is a phase II/III pivotal, randomized, placebo controlled Traumakine study in severely ill COVID-19 patients. The study aims to recruit 350 patients with 1:1 randomization and patients will be followed for ventilation free days (VFD) and mortality over the 28 day period post first dosing. No corticosteroid use will be accepted in this study which is expected to enroll patients over 6-8 months throughout the US with many significant hospitals participating. The study's principal investigator will be Prof. Daniel Talmor from Harvard University's Beth Israel Deaconess Medical Center (BIDMC). Further details will be provided in due course.